OmniSeq is a company that provides molecular diagnostic laboratory services. It utilizes next generation sequencing (NGS) technologies through molecular profiling and offers a range of pharmaceutical services to assist in drug development. The company provides tools enabling medical professionals to identify appropriate treatments specific to a patient’s cancer and immune profile.

Employee Rating

2.5More
TypeSubsidiary
HQBuffalo, NY, US
Founded2015
Websiteomniseq.com
Cybersecurity ratingBMore
OmniSeq was founded in 2015 and is headquartered in Buffalo, NY, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at OmniSeq

Paul Depietro

Paul Depietro

Executive Director, Knowledge Informatics
Margot Schoenborn

Margot Schoenborn

Chief Executive Officer, Director
Roger D. Klein

Roger D. Klein

Chief Medical Officer
Carl Morrison

Carl Morrison

Founder
Sean Glenn

Sean Glenn

SVP, Laboratory Operations and Research Development, Assistant Laboratory Director
Shengle Zhang

Shengle Zhang

Laboratory Director
Show more

OmniSeq Office Locations

OmniSeq has an office in Buffalo
Buffalo, NY, US (HQ)
Hauptman Woodward Medical Research Institute, 700 Ellicott St
Show all (1)

OmniSeq Financials and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$11.6 m

Investors

In total, OmniSeq had raised $11.6 m

OmniSeq Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

OmniSeq Online and Social Media Presence

Embed Graph

OmniSeq Company Culture

  • Overall Culture

    C

    70/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    95/100

Learn more on Comparably

OmniSeq News and Updates

OmniSeq and UPMC Collaborate to Launch Novel Phase II Prospective Head and Neck Cancer Clinical Study

BUFFALO, N.Y., Jan. 28, 2021 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing in oncology, today announced its collaboration with the University of Pittsburgh Medical Center (UPMC) to employ its RNA sequencing (RNA-seq) gene expression profile assay for selecting...

OmniSeq Receives ISO Certification for Quality Management Systems

BUFFALO, N.Y., Dec. 1, 2020 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the company has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management Systems (QMS). ISO 13485:2016...

OmniSeq Blogs

Medical Laboratory Scientist

POSITION SUMMARY The Medical Laboratory Scientist is responsible for specimen processing, test performance and for reporting test results. Performs high complexity molecular laboratory test procedures in a timely manner as assigned; obtains and interprets data for diagnosis and treatment of disease;…

Director, Biopharma Sales & Business Development – Oncology

This position is field based and will promote the company’s genomic and immunoncology portfolio of services targeting early biomarker discovery, translational research, clinical trials, and cancer vaccine development. The Director Biopharma Sales & Business Development will be responsible for se…

Research Laboratory Scientist

POSITION SUMMARY Performs supervised simple and complex molecular tests in the Research and Development (R&D) laboratory to optimize oncology-based assay processes; including sample preparation, workflow, automation and analyte detection to support OmniSeq’s molecular diagnostic testing business…

Cancer-testis antigen detection by targeted RNA sequencing

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as good candidate targets for cance…

Cancer testis antigen co-expression landscape in solid tumors

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for cancer vaccinations and T-cell-ba…

PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer

Yong Hee Lee, Grace Dy, Paul DePietro, Jeffrey Conroy, Sarabjot Pabla and Mary Nesline Abstract Background PD-L1 immunohistochemistry (IHC) testing is suboptimal for predicting patient clinical benefit for checkpoint inhibition, while PD-L1 liquid biopsy is not clinically validated and lacks sensiti…
Show more

OmniSeq Frequently Asked Questions

  • When was OmniSeq founded?

    OmniSeq was founded in 2015.

  • Who are OmniSeq key executives?

    OmniSeq's key executives are Paul Depietro, Margot Schoenborn and Roger D. Klein.

  • How many employees does OmniSeq have?

    OmniSeq has 45 employees.

  • Who are OmniSeq competitors?

    Competitors of OmniSeq include Bioheng, Sunway and Immunetune.

  • Where is OmniSeq headquarters?

    OmniSeq headquarters is located at Hauptman Woodward Medical Research Institute, 700 Ellicott St, Buffalo.

  • Where are OmniSeq offices?

    OmniSeq has an office in Buffalo.

  • How many offices does OmniSeq have?

    OmniSeq has 1 office.